By August 27, 213 companies in the Shenzhen-listed biotech and pharmaceutical sector had released their 2026 interim reports, with over half reporting profit growth. Among them, 34 firms posted year-on-year earnings growth exceeding 100%, 11 grew between 50% and 100%, and 16 managed to swing back to profitability. The surge in innovative drug sales, the closing of out-licensing deals, and rising volumes and prices for core products were the main engines behind the sector's robust performance.
Driven by both innovative drug sales and licensing revenue, Haisco Pharmaceutical Group reported first-half revenue of RMB 3.096 billion, up 54.71% year-on-year. Net profit attributable to shareholders jumped 426.98% to RMB 851 million, while non-GAAP net profit rose 324.18% to RMB 752 million. During the reporting period, the company's domestic sales of innovative drugs maintained rapid growth, and it completed multiple out-licensing agreements, booking substantial upfront payments. Despite R&D expenses climbing over 50% year-on-year, net profit still grew at a robust pace.
Looking to the second half, Haisco said it will continue to push forward clinical trials for several Class 1 new drug candidates, advancing multiple products into pivotal Phase III studies and the filing stage for market approval. At the same time, it will deepen market promotion for its four approved Class 1 innovative drugs—Ciprofol Injection, Crisugabalin Capsules, Kogrliptin Tablets, and Anrukinfen Injection—to sustain growth in innovative drug sales.
Dong-E-E-Jiao Co Ltd also posted steady gains in the first half, with revenue reaching RMB 3.155 billion, up 3.39% year-on-year, and net profit attributable to shareholders growing 5.66% to RMB 860 million. The company has been executing its "1238" development strategy under the annual theme of "Growth and Innovation," pushing forward the iterative upgrades of three growth curves. The first curve focuses on core categories of ejiao and qi-blood products, driving volume growth for blockbusters like Ejiao Blocks, Compound Ejiao Syrup, and Taohuaji Ejiao Cake, while expanding into seasonal wellness and younger consumer scenarios. The second curve relies on two brands, "Royal Hunting Ground 1619" and "Zhuangben" Cistanche, to build a differentiated multi-brand matrix. The third curve, based on the "Three Stages of Beauty and Anti-Aging" theory, creates a new paradigm of Oriental aesthetics combining internal nourishment and external care.
Rundu Pharmaceutical Co Ltd achieved first-half revenue of RMB 709 million, up 29.34% year-on-year, with net profit attributable to shareholders surging 212.59% to RMB 40.75 million and non-GAAP net profit up 173.85% to RMB 33.12 million. The company attributed the performance to aggressive expansion of both domestic and overseas sales channels, leading to higher sales volumes of APIs and formulations. Additionally, its subsidiary in Jingmen improved capacity utilization, and expanded production scale drove costs down, collectively boosting sales revenue and gross profit. The company also restructured its R&D focus and resource allocation, strengthened lean production management, and kept operating expenses under control. In the second half, it will stay focused on its core business, maintain stable operations, and deliver better returns to shareholders.
Elsewhere, Yong'an Pharmaceutical Co Ltd, which focuses on its core taurine business and capitalizes on improving industry supply-demand dynamics, posted first-half revenue of RMB 564 million, up 53.44% year-on-year. Net profit attributable to shareholders jumped 247.39% to RMB 43.41 million, while non-GAAP net profit skyrocketed 1,622.35% to RMB 39.36 million.
Overall, the Shenzhen-listed biotech and pharmaceutical sector showed a positive trend in the first half of 2026, characterized by innovation-driven growth, structural optimization, and improving profitability. With continued policy support and rising R&D investment, industry leaders and companies with competitive advantages in niche segments are well-positioned to maintain steady growth momentum in the second half of the year.
Comments